Abstract
Generic formulations represent a way to reduce the costs of brand compounds when their patent is expired. While, the bio-equivalence in generic drugs is guaranteed, some excipients as well as dyes could be different and this could reduce the drug safety. Herein, we report the development of Adverse Drug Reactions (ADRs) in two patients after the switch from brand to generic formulations. We have tested cytochrome P450 enzymes expression as well as drug serum levels. None of these markers were altered. Checking deeply into both patient’s medical history, they harbored poly-sensitivity or allergy to pollen and graminacea and used different active ingredients for different health problems coming from the same generic company Almus®. This company used different dyes and excipients compared to the branded drugs made by distinguished companies. In conclusion, we strongly suggest to both pharmacists and physicians to be careful in giving the advice to change the drug, thinking to reduce health sanitary costs without considering the personal clinical history of each one. Paradoxically this behavior is causing other health issues, bringing to an increase of the overall costs for patients as well as for National Health System.
Keywords: Adverse drug reactions, brand drug, generic drug.
Current Drug Safety
Title:Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Volume: 11 Issue: 1
Author(s): Luca Gallelli, Giuseppe Gallelli, Giuseppe Codamo, Angela Argentieri, Andzelika Michniewicz, Antonio Siniscalchi, Roberta Stefanelli, Erika Cione, Maria C. Caroleo, Paola Longo and Giovambattista De Sarro
Affiliation:
Keywords: Adverse drug reactions, brand drug, generic drug.
Abstract: Generic formulations represent a way to reduce the costs of brand compounds when their patent is expired. While, the bio-equivalence in generic drugs is guaranteed, some excipients as well as dyes could be different and this could reduce the drug safety. Herein, we report the development of Adverse Drug Reactions (ADRs) in two patients after the switch from brand to generic formulations. We have tested cytochrome P450 enzymes expression as well as drug serum levels. None of these markers were altered. Checking deeply into both patient’s medical history, they harbored poly-sensitivity or allergy to pollen and graminacea and used different active ingredients for different health problems coming from the same generic company Almus®. This company used different dyes and excipients compared to the branded drugs made by distinguished companies. In conclusion, we strongly suggest to both pharmacists and physicians to be careful in giving the advice to change the drug, thinking to reduce health sanitary costs without considering the personal clinical history of each one. Paradoxically this behavior is causing other health issues, bringing to an increase of the overall costs for patients as well as for National Health System.
Export Options
About this article
Cite this article as:
Gallelli Luca, Gallelli Giuseppe, Codamo Giuseppe, Argentieri Angela, Michniewicz Andzelika, Siniscalchi Antonio, Stefanelli Roberta, Cione Erika, Caroleo C. Maria, Longo Paola and Sarro De Giovambattista, Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886311207040309
DOI https://dx.doi.org/10.2174/1574886311207040309 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Editorial (Epigenetics: A Paradigm Shift in Understanding Alzheimer’s Disease)
Current Alzheimer Research Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Current Pharmaceutical Design Immune Response Towards Snake Venoms
Inflammation & Allergy - Drug Targets (Discontinued) New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Unravelling the Genetic Susceptibility to Develop Ligament and Tendon Injuries
Current Stem Cell Research & Therapy Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s Disease: Retrospective Medical Record Review Study and a Nested Case-control Design
Current Alzheimer Research Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry